Shares of ResMed Inc. RMD rallied 3.82% to $213.00 Monday, on what proved to be an all-around rough trading session for the ...

Home CPAP device maker Resmed is launching a small, disposable wearable to help diagnose cases of obstructive sleep apnea.  | ...

Early CPAP treatment for individuals with OSA may help reduce the onset of Parkinson disease and other neurodegenerative diseases.

NightOwl, an FDA-cleared home sleep apnea test (HSAT) offers a simplified, accurate, efficient way to diagnose obstructive sleep apnea (OSA). It adds another offering to Resmed’s portfolio, which is ...

Which is the better option for ASX investors, Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) or ResMed Inc. (ASX: RMD) ...

We recently published a list of Jim Cramer is Discussing These 10 Stocks Ahead of Q1 Earnings Season. In this article, we are ...

A big reason for Resmed’s recently announced rebrand is to reflect its increased direct-to-consumer engagement on obstructive ...

The study, led by global experts in sleep and respiratory medicine and supported by Resmed, found that people with OSA who use CPAP therapy have: A 37% lower risk of dying from any cause compared ...

Resmed (RMD) announced the publication of a meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Many investors also have a go-to methodology that helps guide their buy ...